Date:12/3/2012

luding statements about future performance, expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Healthcare Holdings Group, Inc.'s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "project," "maintain," "plan," and "continue," or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, the risk our products and services are not adopted or viewed favorably by the healthcare community and retail market, both in the U.S. and internationally; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; product integration in physician practices and hospitals; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product introductions; scheduling; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry both in the U.S. and internationally; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining a
'/>"/>

Source: PRWeb Copyright©2012 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
2. C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes
3. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
4. A molecule central to diabetes is uncovered
5. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
6. Novo Nordisk To Award $80,000 To Local Programs That Help People Living With Diabetes In Detroit As Part Of Educational Initiative
7. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
8. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
9. Low testosterone levels could raise diabetes risk for men
10. New Findings of Daily Consumption of Soy Isoflavones and Cacao-Flavonoids in Diabetes Type 2 Patients
11. Gut Microbiota Transplantation may Prevent Development of Diabetes and Fatty Liver Disease